Novartis Beats Failure-To-Warn Suit Over Zometa, Jury Rules

Law360, New York (June 26, 2013, 10:43 PM EDT) -- Novartis Pharmaceuticals Corp. defeated a cancer patient’s claims that she suffered a jaw disease after taking its cancer therapy drug Zometa when a California federal jury found that the drugmaker was not liable for failure to warn of such side effects. 

The jury verdict caps a trial that began June 10, with U.S. District Judge Jed Rakoff handing a final judgment Tuesday releasing Novartis from all claims by plaintiff Chris Hill. Initially bringing her suit in California state court in 2006, Hill had claimed she developed...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Hill v. Novartis Pharmaceuticals


Case Number

1:06-cv-00939

Court

California Eastern

Nature of Suit

Personal Inj. Prod. Liability

Judge

Jed S. Rakoff

Date Filed

July 18, 2006

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.